Depot medroxyprogesterone acetate for contraception: a continuing controversy.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001943:Breast Neoplasms / Q000139:chemically induced; D003270:Contraceptive Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D003906:Developing Countries; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007774:Lactation; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000009:adverse effects; D008598:Menstruation / Q000187:drug effects; D011247:Pregnancy; D014481:United States; D014486:United States Food and Drug Administration; D014594:Uterine Neoplasms / Q000139:chemically induced
D003270:Contraceptive Agents; D003692:Delayed-Action Preparations; D008525:Medroxyprogesterone